In an article originally published in JAMA Neurology, the authors state that long-term clinical and cinematic follow-up point to young-onset tremor-dominant idiopathic Parkinson’s disease rather than boxing injury.

The authors determined the prognostic significance of CTC enumeration and the evolution of both CTC enumeration and the HP ratio over time in the largest longitudinal CTC study in mRCC to date. Potential biomarkers to predict and track response to immunotherapy in mRCC are provided by these insights into changes in both tumor burden and the molecular profile of tumor cells in response to various treatments.

The 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with the generation of ERBB2-specific type 1 T cells in the majority of patients with ERBB2-expressing breast cancer in this phase 1 nonrandomized clinical trial, and it is currently being assessed in randomized phase 2 trials.

The CRc rate was higher with GIL + AZA than with AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy. In addition, OS did not differ significantly between GIL + AZA and AZA in FLT3mut+ AML patients who were not suitable for intensive chemotherapy.

The FDA Oncologic Drugs Advisory Committee (ODAC) unanimously decided on October 28 that there is insufficient evidence to support the claim that the pediatric oncology drug 131-I-omburtamab improves overall survival. A radiolabeled antibody, 131-I-omburtamab was created to treat central nervous system/leptomeningeal (CNS/LM) metastases in pediatric patients with neuroblastoma.

The controversial 2016 CDC opioid guideline for chronic pain is updated and replaced by the new guidance, which addresses acute, subacute, and chronic pain for primary care and other clinicians. Some organizations misapplied the 2016 guideline, which was perceived as imposing strict opioid dose and duration limits. As a result, the guideline authors clarified their recommendations in 2019.